Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SNN 
Smith & Nephew SNATS Inc (SNN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SNN (3-star) is a STRONG-BUY. BUY since 69 days. Profits (29.26%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $35.83
1 Year Target Price $35.83
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.71% | Avg. Invested days 40 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 15.98B USD | Price to earnings Ratio 32.7 | 1Y Target Price 35.83 |
Price to earnings Ratio 32.7 | 1Y Target Price 35.83 | ||
Volume (30-day avg) 4 | Beta 0.62 | 52 Weeks Range 23.30 - 36.84 | Updated Date 08/15/2025 |
52 Weeks Range 23.30 - 36.84 | Updated Date 08/15/2025 | ||
Dividends yield (FY) 2.08% | Basic EPS (TTM) 1.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate 1.03 | Actual 0.43 |
Profitability
Profit Margin 8.26% | Operating Margin (TTM) 14.49% |
Management Effectiveness
Return on Assets (TTM) 5.81% | Return on Equity (TTM) 9.14% |
Valuation
Trailing PE 32.7 | Forward PE 15.46 | Enterprise Value 18819650437 | Price to Sales(TTM) 2.69 |
Enterprise Value 18819650437 | Price to Sales(TTM) 2.69 | ||
Enterprise Value to Revenue 3.17 | Enterprise Value to EBITDA 14.16 | Shares Outstanding 436406016 | Shares Floating 864647372 |
Shares Outstanding 436406016 | Shares Floating 864647372 | ||
Percent Insiders 0.03 | Percent Institutions 8.66 |
Upturn AI SWOT
Smith & Nephew SNATS Inc
Company Overview
History and Background
Smith & Nephew was founded in 1856 in Hull, England. SNATS Inc. is a US entity that is part of Smith & Nephew. The company has evolved from a small pharmacy to a global medical technology company focusing on orthopaedics, advanced wound management, and sports medicine.
Core Business Areas
- Orthopaedics: Focuses on joint reconstruction, trauma, and sports medicine implants and instruments, helping patients regain mobility and independence.
- Advanced Wound Management: Offers products and therapies for chronic and acute wounds, including dressings, negative pressure wound therapy, and biologics, aimed at promoting faster healing and reducing complications.
- Sports Medicine: Develops and markets surgical and non-surgical products and procedures used to repair or regenerate damaged tissue in the knee, hip, and shoulder.
Leadership and Structure
The leadership team consists of key executives in areas like R&D, marketing, finance, and operations. The organizational structure is divided along business unit lines (Orthopaedics, Wound Management, Sports Medicine) with centralized support functions.
Top Products and Market Share
Key Offerings
- ORTHOPLAST: A range of casting and splinting products used in orthopaedics for fracture management and immobilization. Competitors include 3M and BSN Medical. Data on ORTHOPLAST specific market share is difficult to obtain.
- ALLEVYN Life: A multi-layered wound dressing designed for pressure ulcer prevention and management. Competitors include Mu00f6lnlycke Health Care's Mepilex range and Convatec's Aquacel. Allevyn is one of Smith & Nephew's top wound care brands but market share data isn't broken out for this specific product.
- NOVOSTITCH: A meniscal repair system used in sports medicine to address meniscus tears. Competitors include Stryker, and Arthrex. NovoStitch is a significant product in Smith & Nephew's sports medicine portfolio, but specific revenue figures are not typically disclosed.
Market Dynamics
Industry Overview
The medical technology industry is driven by aging populations, increasing prevalence of chronic diseases, and technological advancements. Demand is high for innovative products that improve patient outcomes and reduce healthcare costs. Regulatory compliance and reimbursement pressures are key challenges.
Positioning
Smith & Nephew holds a strong position in the orthopaedics, advanced wound management, and sports medicine markets. Its competitive advantages include a diverse product portfolio, global presence, and strong relationships with healthcare professionals.
Total Addressable Market (TAM)
The global medical technology market is projected to reach hundreds of billions of dollars. Smith & Nephew is well-positioned to capture a significant share of this market through continued innovation and strategic expansion.
Upturn SWOT Analysis
Strengths
- Global brand recognition
- Diversified product portfolio
- Strong distribution network
- Innovation in key product areas
- Established relationships with healthcare providers
Weaknesses
- Dependence on mature markets
- Price competition in commoditized segments
- Exposure to currency fluctuations
- Slower growth compared to some competitors
Opportunities
- Expansion into emerging markets
- Strategic acquisitions of complementary businesses
- Development of new technologies and therapies
- Increased focus on digital health solutions
Threats
- Intense competition from larger players
- Regulatory changes impacting product approvals
- Reimbursement pressures from healthcare payers
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- Johnson & Johnson (JNJ)
- Stryker Corporation (SYK)
- Medtronic (MDT)
- Zimmer Biomet (ZBH)
Competitive Landscape
Smith & Nephew faces competition from larger, more diversified players like Johnson & Johnson, Stryker, and Medtronic. Its strengths lie in its specialized product lines and strong brand reputation in specific areas. However, it may lack the scale and resources of its larger competitors.
Major Acquisitions
Cartiva
- Year: 2018
- Acquisition Price (USD millions): 275
- Strategic Rationale: Expanded Smith & Nephew's sports medicine portfolio with a novel treatment for osteoarthritis in the great toe.
Osiris Therapeutics
- Year: 2019
- Acquisition Price (USD millions): 660
- Strategic Rationale: Bolstered Smith & Nephew's advanced wound management capabilities with a portfolio of regenerative medicine products.
Growth Trajectory and Initiatives
Historical Growth: Financial data for SNATS Inc. is unavailable because it is a subsidiary. Instead, financials will reflect that of Smith & Nephew (SNN). These should not be attributed to Smith & Nephew SNATS Inc. as that entity does not have public financial data.
Future Projections: Financial data for SNATS Inc. is unavailable because it is a subsidiary. Instead, financials will reflect that of Smith & Nephew (SNN). These should not be attributed to Smith & Nephew SNATS Inc. as that entity does not have public financial data.
Recent Initiatives: Financial data for SNATS Inc. is unavailable because it is a subsidiary. Instead, financials will reflect that of Smith & Nephew (SNN). These should not be attributed to Smith & Nephew SNATS Inc. as that entity does not have public financial data.
Summary
Smith & Nephew is a well-established medical technology company with a diversified portfolio and strong brand recognition. The company faces intense competition in a rapidly evolving industry. Key challenges include managing costs, driving innovation, and expanding into emerging markets. The company is strong in sports medicine, advanced wound care and orthopedics.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Annual Reports
- Industry Reports
- Analyst Reports
- Market Data Providers
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly, and actual results may differ from projections. Market share data is often based on estimates and may vary across sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Smith & Nephew SNATS Inc
Exchange NYSE | Headquaters - | ||
IPO Launch date 1999-11-16 | CEO & Director Dr. Deepak S. Nath Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17000 | Website https://www.smith-nephew.com |
Full time employees 17000 | Website https://www.smith-nephew.com | ||
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.